BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Gao YX, Ning QQ, Yang PX, Guan YY, Liu PX, Liu ML, Qiao LX, Guo XH, Yang TW, Chen DX. Recent advances in recurrent hepatocellular carcinoma therapy. World J Hepatol 2023; 15(4): 460-476 [PMID: 37206651 DOI: 10.4254/wjh.v15.i4.460]
URL: https://www.wjgnet.com/1007-9327/full/v15/i4/460.htm
Number Citing Articles
1
Albert Qin, Chang-Ru Wu, Ming-Chih Ho, Chan-Yen Tsai, Pei-Jer Chen. Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical ResultsInternational Journal of Molecular Sciences 2023; 25(1): 433 doi: 10.3390/ijms25010433
2
Shiheng Wu, Xinxing Zhang, Jin Bao, Naiying Sun, Wenjun Guo, Baogui Wang, Xingjie Yang. Hepatocellular carcinoma‑cavernous hemangioma collision tumor: A case reportOncology Letters 2023; 27(2) doi: 10.3892/ol.2023.14207
3
Abhimati Ravikulan, Kamran Rostami. Leveraging machine learning for early recurrence prediction in hepatocellular carcinoma: A step towards precision medicineWorld Journal of Gastroenterology 2024; 30(5): 424-428 doi: 10.3748/wjg.v30.i5.424
4
Zijie Wu, Zehua Dong, Jiangti Luo, Weiwei Hu, Yue Tong, Xiangdong Gao, Wenbing Yao, Hong Tian, Xiaosheng Wang. A comprehensive comparison of molecular and phenotypic profiles between hepatitis B virus (HBV)-infected and non-HBV-infected hepatocellular carcinoma by multi-omics analysisGenomics 2024; 116(3): 110831 doi: 10.1016/j.ygeno.2024.110831